<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03617432</url>
  </required_header>
  <id_info>
    <org_study_id>CSIIT-T13</org_study_id>
    <nct_id>NCT03617432</nct_id>
  </id_info>
  <brief_title>Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients</brief_title>
  <official_title>Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University International Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangxi Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for
      Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase
      II Clinical Trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chidamide，a novel histone deacetylase inhibitor has been approved for the treatment of
      relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to
      observe the efficacy and safety of Chidamide With Cyclophosphamide, Doxorubicin, Vincristine,
      Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete remission (CR）rate</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The rate of patients who achieve complete remission after the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate（ORR）</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The total proportion of patients with complete response（CR）and partial response（PR）.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival（PFS）</measure>
    <time_frame>2 years</time_frame>
    <description>Time from treatment until disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival（OS）</measure>
    <time_frame>2 years after the last patient's enrollment.</time_frame>
    <description>From the date of inclusion to date of death, irrespective of any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Experimental Tumor</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group will be treated by Chidamide combined CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control group will be treated by CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>Chidamide 15mg orally BIW. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>epidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide(750mg/m2) was administered intravenously on d1. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine (1.4mg)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide (100mg/m2) was administered intravenously on d1,2,3.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone (100mg)was administered by oral on d1-5.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histopathology / cytology diagnosed as peripheral T cell lymphoma (PTCL) according to
             WHO 2016 classification criteria（NK/T cell lymphoma and ALK positive anaplastic large
             cell lymphoma excluded）including:Peripheral T-cell lymphoma, NOS，Angioimmunoblastic
             T-cell lymphoma，Anaplastic large-cell lymphoma, ALK negative，Enteropathy-associated
             T-cell lymphoma，Hepatosplenic T-cell lymphoma，Subcutaneous panniculitis T-cell
             lymphoma，Mycosis fungoides，Other T-cell lymphoma that investigators consider to be
             appropriate to be enrolled;

          2. Patients have received CHOPE regimen for 2 cycles therapy and achieve PR or SD;

          3. Patients should have at least one evaluable foci ( lymph nodes with diameter≥1.5cm, or
             evaluable skin foci);

          4. Age 18-70 years, male or female;

          5. ECOG performance status 0-2;

          6. Absolute neutrophil count ≥1.5×109/L, platelet ≥75×109/L, Hb ≥ 90g/L;

          7. ALT and serum creatinine ＜1.5 times of normal maximum;

          8. Life expectancy no less than 3 months;

          9. Willing to sign the Informed Consent Form.

        Exclusion Criteria:

          1. NK/T cell lymphoma or ALK positive anaplastic large cell lymphoma;

          2. Female patients in lactation or pregnancy, Childbearing female or male patients
             unwilling to take contraceptive measures;

          3. QTc elongation with clinical significance ( male＞ 450ms, female＞ 470ms), ventricular
             tachycardia, atrial fibrillation, cardiac conducting blockage, myocardial infarction
             within 1 year, congestive heart failure, symptomatic coronary heart disease that
             requires treatment;

          4. Patients have undergone organ transplantation;

          5. Patients received symptomatic treatment for bone marrow toxicity within 7 days prior
             to enrollment;

          6. Patients with active hemorrhage;

          7. Patients with or with history of thrombosis, embolism, cerebral hemorrhage, or
             cerebral infarction;

          8. Patients with active infection or continuous fever within 14 days prior to enrollment;

          9. Had major organ surgery within 6 weeks prior to enrollment;

         10. Impaired liver function ( Total bilirubin ＞ 1.5 times of normal maximum, ALT/AST＞ 2.5
             times of normal maximum, for patients with infiltrative liver disease ALT/AST＞ 5 times
             of normal maximum), impaired renal function (serum creatinine＞ 1.5 times of normal
             maximum);

         11. Patients with mental disorders or those do not have the ability to consent;

         12. Patients with drug abuse, long term alcoholism that may impact the results of the
             trial;

         13. Patients with invasion of central nervous system ;

         14. Non-appropriate patients for the trial according to the judgment of the investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Zhu, Dr.</last_name>
    <phone>010-88140650</phone>
    <email>dreaming2217@hotmai.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuqin Song, Dr.</last_name>
    <phone>010-88140650</phone>
    <email>songyuqin622@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhu, MD</last_name>
      <phone>+86-10-88196596</phone>
      <email>zj@bjcancer.org</email>
    </contact>
    <contact_backup>
      <last_name>Weiping Liu, MD</last_name>
      <phone>+86-10-88196109</phone>
      <email>dreaming2217@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jun Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>August 30, 2018</last_update_submitted>
  <last_update_submitted_qc>August 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Jun Zhu</investigator_full_name>
    <investigator_title>Director of lymphoma department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Neoplasms, Experimental</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

